A randomized, single center, double blind, two treatment,Two-period, crossover glucose clamp study to test forBioequivalence between biphasic isophane insulin injectionsWockhardtâ??s wosulinÂ® 30/70 and actraphane 30 , in healthySubjects - W-WOS(M)-106

Wockhardt Bio AG0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Subjects weight within the normal range according to normal
•values for the Body Mass Index with minimum of 50 kg weight.
•3. Subjects with normal health as determined by medical history, clinical examination and laboratory examinations within the
•clinically acceptable normal range.
•4. Subjects having clinically acceptable 12-lead electrocardiogram (ECG).
•5. Subjects having clinically acceptable chest X-Ray (PA view).

•1.Hypersensitivity to Insulin or related class of drugs.
•2. History or presence of significant cardiovascular, pulmonary,hepatic, renal, gastrointestinal, endocrine, immunological,
•dermatological, neurological or psychiatric disease or disorder.
•3. Any treatment which could bring about induction or inhibition
•of hepatic microsomal enzyme system within 1 month of the study drug administration.
•4. History or presence of significant alcoholism or drug abuse in the past one year.

发起方